Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs

Journal of Pharmaceutical Sciences
K M Wasan, S M Cassidy

Abstract

The plasma lipoprotein distribution of potential drug candidates is not commonly studied. For some hydrophobic drug candidates, attainment of similar plasma free drug levels has not been associated with uniform production of pharmacological activity in different animal species. It is well-known that plasma lipoprotein lipid profiles vary considerably between different animal species. In addition, human disease states can significantly influence plasma lipoprotein profiles, resulting in altered therapeutic outcomes. Current research has shown that lipoprotein binding of drug compounds can significantly influence not only the pharmacological and pharmacokinetic properties of the drug, but the relative toxicity as well. Elucidation of drug distribution among plasma lipoproteins is expected to yield valuable insight into factors governing the pharmacological activity and potential toxicity of the drug. This paper will present an historical perspective and summarize the latest research in the area of lipoprotein-drug interactions.

References

Jan 1, 1977·Annual Review of Biochemistry·J L Goldstein, M S Brown
Mar 1, 1979·Clinical Pharmacology and Therapeutics·A Danon, Z Chen
Dec 1, 1992·Annals of Tropical Medicine and Parasitology·S MohantyT K Bose
Dec 16, 1991·Biochemical and Biophysical Research Communications·J BarwiczI Gruda
Dec 1, 1990·Journal of the American Academy of Dermatology·W M Bennett
Sep 1, 1985·Journal of Cardiovascular Pharmacology·S UrienJ P Tillement
Apr 1, 1989·Antiviral Research·D R PontaniP S Sarin
May 9, 1989·Biochimica Et Biophysica Acta·W J Schneider
Apr 1, 1989·Journal of Pharmaceutical Sciences·G G ChabotL H Baker
Jul 1, 1989·British Journal of Clinical Pharmacology·K A MiltonA M Breckenridge
Aug 1, 1986·The Journal of Pharmacy and Pharmacology·D SgoutasI Jerkunica
Jan 1, 1985·Annual Review of Cell Biology·J L GoldsteinW J Schneider
Oct 1, 1986·Scottish Medical Journal·R J NorthcoteD Ballantyne
Jan 1, 1989·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·C Y YangA M Gotto
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·R B WeissB Leyland-Jones
Jan 1, 1988·Annals of the New York Academy of Sciences·G Lopez-Berestein
Oct 1, 1987·The New England Journal of Medicine·P C de GroenR A Krom
Apr 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A S JarnaginC Fielding
Apr 4, 1986·Science·M S Brown, J L Goldstein
Jan 1, 1986·Methods in Enzymology·A M GottoR J Havel
Aug 14, 1987·Biochemical and Biophysical Research Communications·R J CushleyD B Fenske
Nov 1, 1982·The Journal of Pharmacy and Pharmacology·M Lemaire, J P Tillement
Mar 21, 1980·Biochimica Et Biophysica Acta·O V RajaramP J Barter
Jan 1, 1983·Annual Review of Pharmacology and Toxicology·G MedoffJ Bolard

❮ Previous
Next ❯

Citations

Aug 12, 2005·Cancer Chemotherapy and Pharmacology·Kishor M WasanSheila Pritchard
Oct 29, 2008·Pharmaceutical Research·Mei-Ling Chen, Vincent H L Lee
Apr 28, 2004·Advanced Drug Delivery Reviews·Nancy S Chung, Kishor M Wasan
Mar 11, 2004·International Journal of Pharmaceutics·Junzo SekiTadanori Mayumi
Dec 11, 2013·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Ryan MatsudaDavid S Hage
Feb 26, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Michelle P McIntoshChristopher J H Porter
Aug 8, 2001·Advanced Drug Delivery Reviews·C J Porter, W N Charman
Dec 14, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ric M ProcyshynKishor M Wasan
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Karen BartlettKishor M Wasan
Oct 17, 2006·Clinical Microbiology Reviews·Joseph MeletiadisThomas J Walsh
May 30, 2003·American Journal of Respiratory and Critical Care Medicine·Luis A AugustoRichard Chaby
Jul 18, 2001·Chemical & Pharmaceutical Bulletin·M L Go, S S Feng
Mar 4, 2003·Chemical & Pharmaceutical Bulletin·Mei-Lin Go, Qiu-Tian Li
Nov 3, 2005·Environmental Health Perspectives·Ricky T WoofterJohn S Ramsdell
Jun 4, 2011·Expert Opinion on Drug Metabolism & Toxicology·Mario PellegattiDimitri Colato
Nov 25, 2005·Drug Development and Industrial Pharmacy·Ric M ProcyshynKishor M Wasan
Sep 21, 2013·Expert Opinion on Drug Metabolism & Toxicology·Anne Lespine
Dec 18, 2001·Journal of Pharmaceutical Sciences·K D Peteherych, K M Wasan
May 16, 2003·Phytotherapy Research : PTR·Zdenek SvageraVilím Simánek
Jul 5, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Mitsunori HaradaYasuki Kato
Jan 18, 2011·Advanced Drug Delivery Reviews·L BildsteinP Couvreur
Jun 15, 2007·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Pavel GershkovichAmnon Hoffman
Jul 3, 2007·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Pavel Gershkovich, Amnon Hoffman
Nov 13, 2004·Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP·Mohamad Firas BassissiAnne Lespine

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.